Sagimet Biosciences Inc (SGMT)
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing fatty acid synthase (FASN) inhibitors for diseases linked to metabolic and fibrotic dysfunction. Its lead candidate, denifanstat, is an oral once-daily selective FASN inhibitor being studied for metabolic dysfunction-associated steatohepatitis, acne, and certain cancers. The company is also advancing TVB-3567 for acne, along with oncology programs that include solid tumor and glioblastoma research. Formerly known as 3-V Biosciences, Inc., the company adopted its current name in August 2019. Sagimet Biosciences was incorporated in 2006 and is based in San Mateo, California. Its common stock trades on the NASDAQ under the symbol SGMT.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SGMT
|
$6.06
|
-14.3% Downside
|
Fair
|
$26.20
|
270.6% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-10.1x
|
4.3x
|
—
|
442.1 M
|
335.2 M
|
0.0%
|
95.8%
|
45.1
|
—
|
91.3%
|
